Long-term treatment for IgA nephropathy
This study tests a long-term treatment for people with IgA nephropathy, a kidney disease. It aims to see if continuing the treatment is safe and helpful over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already completed the previous FXS6837 study and your doctor thinks continuing treatment is beneficial.
- Your kidney function must be at a certain level (eGFR of 30 or higher).
- You need to have had vaccines for meningitis and pneumonia, and may need a booster.
- You must be able to keep taking your current kidney medications at a stable dose.
- You must agree to use effective birth control if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help protect kidney function. Participants must have a recent kidney biopsy showing certain features and stable kidney function.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
This trial tests a new treatment called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can safely reduce protein in the urine and help protect kidney function.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
Hear when a new Primary IgAN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.